Meeting
2017 Gastrointestinal Cancers Symposium
A phase II Study of FOLFOX versus POF (paclitaxel plus FOLFOX) versus IP PAC (intraperitoneal paclitaxel) plus FOLFOX as a first-line treatment in advanced gastric cancer (AGC): A feasibility analysis.
Authors
Rongbo Lin
Fujian Provincial Cancer Hospital, Fuzhou, China
Rongbo Lin , Shen Zhao , Hui Li , Jie Liu , Nanfeng Fan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Translational Research
Clinical Trial Registration Number
NCT02845908
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 56)
DOI
10.1200/JCO.2017.35.4_suppl.56
Abstract #
56
Poster Bd #
F12
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Final survival results from a multicenter, randomized phase II trial of intravenous paclitaxel plus FOLFOX (ivPOF) and/or intraperitoneal paclitaxel plus FOLFOX (ipPOF) versus mFOLFOX6 as first-line treatment of advanced gastric cancer (AGC): SYLT/FNF 004.
First Author: Shen Zhao
Poster
2019 ASCO Annual Meeting
POF (paclitaxel plus FOLFOX) versus IP PAC (intraperitoneal paclitaxel plus FOLFOX) versus FOLFOX as a first-line treatment in advanced gastric cancer (AGC): Update from a multicenter, randomized phase II trial, FNF-004 trial.
First Author: Rongbo Lin
Poster
2012 ASCO Annual Meeting
PaFLO: Pazopanib with 5-fluorouracil, leucovorin, and oxaliplatin (FLO) as first-line treatment in advanced gastric cancer: A randomized phase II study of the Arbeitsgemeinschaft internistische Onkologie (AIO).
First Author: Kirstin Breithaupt
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Tislelizumab combined with POFI (irinotecan, paclitaxel, oxaliplatin and 5-FU/levoleucovorin) as first-line treatment of advanced gastric/gastroesophageal junction adenocarcinoma (AGC): Preliminary results of a single-arm, open-label phase I/II trial (SYLT-023).
First Author: Rongbo Lin